Midland Health wants to make it easy for people to ask about an experimental COVID-19 treatment.
The health care company has created an online form for community members to submit questions about the treatment, Bamlanimivimab.
The Bamlanimivimab treatment is an experimental treatment meant to help prevent high-risk people from being hospitalized from COVID-19, Midland Health said in a release.
To be eligible for the treatment, patients need to have tested positive for the coronavirus less than 72 hours ago and their symptoms cannot have been present for more than four days.
"Patients must ALSO have one of the following: Obesity (BMI>35), chronic kidney disease, diabetes, immunosuppressive disease or be receiving immunosuppressive treatments," Midland Health said in the release. "Patients older than 65 qualify if they also have cardiovascular disease, hypertension, or a chronic respiratory disease, such as COPD."
The treatment is only available to outpatients. Hospitalized patients or those that need oxygen support are not eligible for the treatment.
"If you believe you meet the criteria, please complete the form at midlandhealth.org/MAIS. Upon receipt and review of the form, a Midland Health employee will follow up on the inquiry," Midland Health wrote in the press release.